Hellmund M, Bajorat J, Machmüller S, Sauer M, Zitzmann A, Reuter D A, Mencke T
Klinik und Poliklinik für Anästhesiologie und Intensivtherapie, Universitätsmedizin Rostock, Schillingallee 35, 18057, Rostock, Deutschland.
Anaesthesist. 2018 Jul;67(7):488-495. doi: 10.1007/s00101-018-0454-1. Epub 2018 May 25.
Mask ventilation could improve after administration of muscle relaxants if there is a functional obstruction of the airway, such as laryngospasm, vocal cord closure or opioid-induced muscle rigidity. On the other hand, muscle relaxants could worsen mask ventilation because they induce upper airway collapse; however, clinical studies showed that rocuronium (Roc) improved mask ventilation or it remained unchanged. In most cases Roc 0.06 mg/kgBW was used.
The optimal dose of Roc has not been studied; therefore, we studied the quality of mask ventilation with three different doses of Roc (0.3, 0.6 and 0.9 mg/kgBW) and compared them with a control group receiving saline.
In this prospective clinical trial 200 patients were randomized into 4 groups: NaCl (saline), Roc03 (Roc 0.3 mg/kgBW), Roc06 (Roc 0.6 mg/kgBW) and Roc09 (Roc 0.9 mg/kgBW). Mask ventilation was performed to reach a tidal volume (TV) of >5.0 ml/kgBW; maximum ventilation peak pressure (p) was limited to 25 mbar. If this TV was not reached, mask ventilation was improved by better mask position, head position or/and usage of a Guedel tube (oropharyngeal airway). During mask ventilation p and TV were recorded and the quality of mask ventilation was assessed with the Han and Warters scores. The quality of mask ventilation between the four groups was compared for all patients and a subgroup analysis was performed for patients of the study groups, who had to be ventilated with a Guedel tube and for obese patients (body mass index ≥26 kg/m). A sample size calculation revealed that at least 38 patients were necessary for each group to detect a statistically significant difference between groups; it was assumed that Roc improved the efficacy of mask ventilation by 20% compared to saline (α = 0.05, 1-β = 0.8).
The administration of Roc significantly improved the TV/p ratio compared to saline (p = 0.04); however, this effect was irrespective of the dose. In patients who were ventilated with the Guedel tube the TV/p ratio increased after Roc03 (p ≤ 0.01) and after Roc06 (p < 0.02) compared to the saline group. In obese patients who were ventilated with the Guedel tube the TV/p ratio increased after Roc03 (p ≤ 0.01), after Roc06 (p = 0.03) and after Roc09 (p = 0.02) compared to the saline group. There were no significant differences between the Roc groups; however, the effect was more pronounced in the Roc03 patients compared to the other Roc groups. The Han and Warters scores were not significantly different between the Roc groups and the saline group.
The efficacy of mask ventilation was equal or improved after administration of Roc but did not become worse. Patients who were ventilated with a Guedel tube had higher TV/p ratios after Roc03 and Roc06 compared to saline. Higher dosages (>Roc06), however, had no advantages concerning quality of mask ventilation. In obese patients who had to be ventilated with a Guedel tube, Roc also improved the efficacy of mask ventilation. We conclude that administration of Roc is effective in improving mask ventilation and this effect was seen after 30-60 s even after Roc03.
如果存在气道功能性梗阻,如喉痉挛、声带闭合或阿片类药物引起的肌肉强直,使用肌肉松弛剂后面罩通气可能会改善。另一方面,肌肉松弛剂可能会使面罩通气恶化,因为它们会导致上气道塌陷;然而,临床研究表明,罗库溴铵(Roc)可改善面罩通气或使其保持不变。在大多数情况下,使用的罗库溴铵剂量为0.06 mg/kg体重。
尚未研究罗库溴铵的最佳剂量;因此,我们研究了三种不同剂量的罗库溴铵(0.3、0.6和0.9 mg/kg体重)面罩通气的质量,并将其与接受生理盐水的对照组进行比较。
在这项前瞻性临床试验中,200名患者被随机分为4组:NaCl(生理盐水)、Roc03(罗库溴铵0.3 mg/kg体重)、Roc06(罗库溴铵0.6 mg/kg体重)和Roc09(罗库溴铵0.9 mg/kg体重)。进行面罩通气以达到潮气量(TV)>5.0 ml/kg体重;最大通气峰值压力(p)限制在25 mbar。如果未达到该潮气量,则通过调整面罩位置、头部位置或/和使用口咽通气管(Guedel管)来改善面罩通气。在面罩通气期间,记录p和TV,并使用Han和Warters评分评估面罩通气质量。比较所有患者四组之间的面罩通气质量,并对必须使用Guedel管通气的研究组患者和肥胖患者(体重指数≥26 kg/m²)进行亚组分析。样本量计算表明,每组至少需要38名患者才能检测到组间的统计学显著差异;假设与生理盐水相比,罗库溴铵可使面罩通气效果提高20%(α = 0.05,1-β = 0.8)。
与生理盐水相比,罗库溴铵的使用显著改善了TV/p比值(p = 0.04);然而,这种效果与剂量无关。在使用Guedel管通气的患者中,与生理盐水组相比,Roc03(p ≤ 0.01)和Roc06(p < 0.02)后TV/p比值增加。在使用Guedel管通气的肥胖患者中,与生理盐水组相比,Roc03(p ≤ 0.01)、Roc06(p = 0.03)和Roc09(p = 0.02)后TV/p比值增加。罗库溴铵组之间无显著差异;然而,与其他罗库溴铵组相比,Roc03患者的效果更明显。罗库溴铵组和生理盐水组之间的Han和Warters评分无显著差异。
使用罗库溴铵后面罩通气效果相等或有所改善,但未变差。与生理盐水相比,使用Guedel管通气的患者在Roc03和Roc06后TV/p比值更高。然而,更高剂量(>Roc06)在面罩通气质量方面没有优势。在必须使用Guedel管通气的肥胖患者中,罗库溴铵也改善了面罩通气效果。我们得出结论,罗库溴铵的使用可有效改善面罩通气,即使在Roc03后30 - 60秒也能看到这种效果。